Videos

AstraZeneca Pays $50 Million For Rights To Merck Cancer Drug

wochit news
|
September 11, 2013 AT 5:13 AM
Merck has licensed its experimental cancer drug to AstraZeneca for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.